281235-04-9

Basic information

• Product Name: 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER
• Synonyms: 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER;Methyl 4-(piperidin-4-yl)benzoate;METHYL 4-PIPERIDIN-4-YL-BENZATE HCL;Methyl 4-piperidin-4-yl-benzate
• CAS NO: 281235-04-9
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.28
• Product Categories: pharmacetical
• Mol File: 281235-04-9.mol

Chemical Properties

• Boiling Point: 340.3°C at 760 mmHg
• Flash Point: 159.6°C
• Appearance: /
• Density: 1.071g/cm³
• Vapor Pressure: 8.65E-05mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER(281235-04-9)
• EPA Substance Registry System: 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER(281235-04-9)

Safety Data

• Hazardous Substances Data: 281235-04-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications due to its potential pharmacological properties.
Used in Research Laboratories:
4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER is used as a research compound for studying various biological processes and aiding in drug discovery, providing insights into the compound's potential applications and effects.
It is crucial to handle 4-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER with care due to its potential hazardous properties, and proper safety precautions should be taken during its use in both pharmaceutical synthesis and research applications.

InChI:InChI=1/C13H17NO2/c1-16-13(15)12-4-2-10(3-5-12)11-6-8-14-9-7-11/h2-5,11,14H,6-9H2,1H3

Upstream product

• 286961-15-7 benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1 (2H)-pyridinecarboxylate 
• 586-76-5 4-Bromobenzoic acid 
• 67-56-1 methanol 
• 196204-01-0 4-(piperidin-4-yl)-benzoic acid 
• 936130-82-4 methyl 4-(piperidine-4-yl)benzoate hydrochloride 
• 106047-17-0 4-Pyridin-4-yl-benzoic acid methyl ester 

Downstream Products

• 354813-48-2 methyl 4-(1-methylpiperidin-4-yl)benzoate 
• 355379-05-4 4-(4-methoxycarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1001548-01-1 4-(1-cycIobutylpiperidin-4-yl)benzoic acid 
• 1001547-97-2 4-(1-cyclopropylpiperidin-4-yl)benzoic acid 
• 1001547-96-1 4-(1-ethylpiperidin-4-yl)-benzoic acid 
• 1620568-72-0 C₁₉H₂₇N₃O₅ 
• 1620568-63-9 methyl 4-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]-4-piperidyl]benzoate 
• 1620568-57-1 methyl 4-(1-cyano-4-piperidyl)benzoate 
• 1127500-08-6 4-(1'-cyclopropylmethyl-2'-oxo-3,4,5,6,1',2'-hexahydro-2H-[1,4']bipyridinyl-4-yl)-benzoic acid 

Relevant articles and documents

BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

NOVEL COMPOUNDS

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Dipeptide nitrile cathepsin K inhibitors

Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 toget